Clinical Trials Browser

Phase 2 × Glioblastoma × pazopanib × Clear all

NCT01931098 2025-08-11

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

Phase 2 Completed

35 enrolled 13 charts

CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT01392352 2020-02-13

HYPAZ

Phase 2 Terminated

31 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Gastrointestinal Neoplasms, Glioblastoma, Hypertension, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Small Cell Lung Carcinoma

NCT00459381 2017-03-15

Pazopanib in Treating Patients With Recurrent Glioblastoma

Phase 2 Completed

35 enrolled 12 charts

CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma